JADPRO Live 2017 Activities
Knowledge Center: Oral Oncolytics
MULTIPLE MYELOMA UPDATES
HER2-POSITIVE BREAST CANCER UPDATES
MYELOPROLIFERATIVE NEOPLASMS UPDATES
Narratives: HER2-Positive Breast Cancer
Overview of Immunotherapy
Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?
Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Is programmed cell death ligand 1 (PD-L1) testing necessary?
When should you image patients to assess response to immunotherapy?
What are the mechanisms of action and adverse effects of these agents?
How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?
What cancers are most likely to respond to immunotherapy?
How do you educate patients about the timing of early and latent side effects?
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.
Bot trap - Don't go here